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Summary
Differentiated thyroid cancer comprises papillary, mixed
papillary-follicular and follicular adenocarcinomas. They
are mostly hormone-sensitive and respond to thyroid-
stimulating hormone (TSH) suppression. The standard
treatment is total thyroidectomy. 131I therapy and thyroid
hormone suppression therapy. Adjuvant external radio-
therapy is discussed controversially. Most authors
recommend adjuvant external radiotherapy for extra-
capsular tumor extension. Decision on an individual basis
should be made for patients with lymph node involve-
ment. In the case of incomplete surgical resection, exter-
nal radiotherapy should be applied if second surgery is
not possible. For medullary thyroid cancer, external beam
radiotherapy seems to be beneficial for patients with surgi-
cally inaccessible disease, with microscopic residual or
gross tumor after surgery, with recurrent locoregional
disease, or with surgically unmanageable metastases.
Patients suffering from anaplastic thyroid cancer should
receive combined treatment consisting of extensive
surgery, external irradiation with total doses up to 60 Gy,
and chemotherapy. The combined treatment modality
leads to higher local control rates and prolongs survival.
Schlüsselwörter
Schilddrüsenkarzinom · Radiojodtherapie – Externe 
Strahlentherapie
Zusammenfassung
Differenzierte Schilddrüsenkarzinome werden in papilläre,
gemischt papillär-follikuläre und follikuläre Adenokarzi-
nome unterteilt. Sie sind meist hormonabhängig und ihr
Wachstum kann durch Thyrotropin (TSH)-Suppression
gehemmt werden. Die Standardtherapie umfaßt totale
Thyroidektomie, postoperative Radiojodtherapie und Hor-
montherapie. Die Rolle der adjuvanten externen Strahlen-
therapie wird kontrovers diskutiert. Von den meisten Auto-
ren wird die Indikation zur externen Strahlentherapie bei
kapselüberschreitendem Tumorwachstum gestellt. Die Indi-
kation bei Lymphknotenbefall sollte individuell gestellt
werden. Bei positiven Resektionsrändern sollte, falls ein
erneutes chirurgisches Vorgehen nicht möglich ist, die
externe Strahlentherapie durchgeführt werden. Bei medul-
lären Schilddrüsenkarzinomen ist die externe Strahlenthe-
rapie bei Inoperabilität, bei postoperativ mikroskopischem
oder makroskopischem Tumorrest, beim loko-regionalen
Rezidiv und bei inoperablen Metastasen indidziert. Bei
Patienten mit anaplastischem Schilddrüsenkarzinom ver-
spricht eine kombinierte Therapie, bestehend aus mög-
lichst weitgehender Tumorentfernung, externer Strahlen-
therapie mit Gesamtdosen um 60 Gy und Chemotherapie,
die beste lokale Kontrolle und das längste Überleben.
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Introduction
The mainstay of treatment for differentiated thyroid cancer 
is surgery, consisting for the majority of patients in a total
thyroidectomy, followed by 131I ablation of the residual thyroid
tissue and thyroid hormone suppression therapy. In the case of
incomplete surgical resection, if a second surgery is not pos-
sible and in patients with extra-capsular tumor extension, addi-
tional external beam radiotherapy is useful to achieve local
control.However, the indication for external beam radiotherapy
is discussed controversially. In this article we summarize the
present treatment options and discuss the situation where
external radiotherapy might be beneficial.
Differentiated Thyroid Cancer
Differentiated thyroid cancer compries of papillary, mixed
papillary-follicular, and follicular adenocarcinoma.
Papillary thyroid cancer is slow-growing and often multi-
centric. It is diagnosed mostly at age 30–50. The prognosis is
excellent. This tumor usually grows infiltrative and metasta-
sizes to regional lymph nodes through lymphatic channels.
Hematogenous metastases are uncommon.
Follicular carcinomas are unifocal, have a marked tendency 
to invade vascular channels, and metastasize hematogenously
to distant sites. Lymph node metastases are uncommon. The
average age at diagnosis is 50–60 years.
The 10-year survival rate of papillary thyroid cancer with
78–91% is better than of follicular thyroid cancer with 66–78%
[1–3]. The more unfavorable outcome of the follicular thyroid
carcinoma may depend on the more common distant metas-
tases and the often higher age at diagnosis.
The mainstay of treatment for differentiated thyroid cancer is
surgery, consisting of a total thyroidectomy and regional
lymphadenectomy, followed by 131I ablation of the residual
thyroid tissue, and thyroid hormone suppression therapy. The
indication for postoperative external radiation of differen-
tiated thyroid cancer has remained an issue of controversial
discussion, especially in the case of microscopic residual
disease. It is generally restricted to those cases where local
tumor control by postoperative 131I therapy alone seems doubt-
ful [4, 5]. Sautter-Bihl et al. [4] analyzed the problem of dose
distribution of 131I -radiation in a simulation model by Monte
Carlo techniques where tumors are tissue-equivalent spheres
of various size.
Homogenous 131I distribution in the whole tumor volume as well
as peripheral deposition confined to the tumor surface was
analyzed. Extensive dose inhomogeneities appeared in small
tumors. As in local lymph node metastases tumoricidal radia-
tion doses are not necessarily achievable by 131I therapy alone,
postoperative external beam radiation should be considered 
in the clinical situation of lymph node involvement or occult
micrometastases.
Gross Residual Disease and Microscopic Residual Disease
One of the earliest reports on the use of external radiotherapy
in thyroid cancer was by Sheline and co-workers [6]. In 1966
they reported on their experience with external radiotherapy
in 58 patients treated between 1935 and 1964. They described
the use of external beam radiotherapy in a variety of thyroid
histologies and clinical situations. Given the time period of the
study, the techniques of radiation used would not be con-
sidered to be adequate today. The applied doses ranged from
30 to 50 Gy, given in 15–50 days. Supplementary 131I therapy
was not performed. 15 patients with papillary and 4 with folli-
cular thyroid cancer had gross residual disease or inoperable
recurrence in the surgical bed. For papillary tumors with
follow-up ranging from 1 to 25 years, 8 patients were alive with
no evidence of disease, and 4 showed local recurrences. Of the
9 patients with palpable disease before external radiotherapy,
7 had a complete response and only 1 patient had a subsequent
local relapse. The response in follicular tumors was similar.
These results suggest that external radiotherapy, even at sub-
optimal doses, may play a role in controlling gross disease in
well-differentiated thyroid cancer and it may also contribute to
local control in patients who following surgery, have micro-
scopic residual disease in the neck. O’Connell et al. [7] described
the Royal Marsden Hospital experience with 113 patients
suffering from differentiated thyroid carcinoma. All of them
were treated with radical external radiotherapy (60 Gy in 
30 fractions, over 6 weeks). All received thyroid hormone
suppression therapy with 74 undergoing additional 131I therapy.
Three subgroups were defined according to residual disease
status. In the probably microscopic residual disease group, 2 of
25 patients (8%) developed an in-field recurrence. In the group
of definite microscopic residual disease 5 of 18 (29%) patients
experienced in-field recurrences. Of the 32 patients with gross
residual disease complete regression occurred in 37%.
Tubiana et al. [8] reported a 40% 15-year relapse-free survival
rate and a 57% 15-year survival rate in 97 patients with gross
residual disease treated with external radiotherapy.
In a review of patients treated at Princess Margaret Hospital
Tsang and co-workers [9] reported on 33 patients with gross
residual disease, 20 were treated with external radiotherapy
only and 13 had 131I in addition to external beam radiotherapy.
The 5-year local relapse-free rate was 62%, and the cause-
specific survival rate was 65%.
Phlips and co-workers [10] reported on 94 patients with dif-
ferentiated thyroid cancer seen in their department from 1974
to 1989. 38 of these patients received a course of postoperative
external irradiation. The indications for additional external
irradiation were directly related to the quality of the surgical
resection. All patients had either macro- or microscopic resid-
ual disease or positive cervical lymph nodes with extracapsular
extension. The results showed that additional external irradia-
tion did not improve survival in this group. The 5-year survival
rates were 94% for the radioiodine group and 84% for the
additional external radiation group. The local relapse rate was
21% for those who received radioiodine only, as compared to
3% for those who also received external beam radiotherapy.
Potential bias could be introduced by the selection of the exter-
nal radiation group, consisting of patients with worse progno-
sis. However, external radiation highly improved the locoregio-
nal control rate in these cases. External beam radiotherapy is a
local therapy given with the intention to reduce the risk of
local relapse.As Phlips et al. stated, local control is certainly an
important endpoint in thyroid cancer treatment because it
avoids problems created by a relapse, such as recurrent nerve
palsy, compression of the esophagus associated with dysphagia,
and invasion of the trachea with hemoptysis. Furthermore, an
increased risk for distant dissemination due to the persistence
of neoplastic tissue is a potential problem.
Extrathyroidal Extension in Differentiated Thyroid Cancer
The influence of external irradiation on survival rate in differen-
tiated carcinomas exceeding organ boundaries was assessed in
the evaluation of treatment results by Leisner and co-workers
[1]. 167 patients with external irradiation (I) and 73 without
external irradiation (II), but otherwise identical treatment, and
differentiated carcinoma stage T3 (stage T4 when modern cri-
teria are used) were compared. Group I showed a 5- and 8-year
survival of 88 and 75%, group II of 68 and 38%, respectively
(p < 0.001). Local recurrence occurred in 10% of both groups.
However, metastases were found more frequently and earlier
in group II (without external beam irradiation). This led the
authors to recommend external radiotherapy in differentiated
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thyroid tumors with extracapsular extension. Therefore,
external beam radiotherapy should be considered for patients
with a risk for relapse of more than 10–20% in the thyroid bed.
It is well recognized that extrathyroidal extension is a poor
prognostic feature in differentiated thyroid cancer.
Samaann et al. [11] demonstrated on 1599 patients, treated at
the M.D.Anderson Cancer Centre, that the risk for local recur-
rence increased with the extension of local tumor. If the tumor
was confined to the thyroid gland, local recurrence rate was
19%, with nodal involvement it increased to 22%; but if there
was infiltration of the soft tissues, it increased to 36%. Survival
at time of follow-up (median 11 years) was 93 and 94% for the
first two groups, respectively, but decreased to 82% in patients
with extrathyroidal extension and soft tissue involvement.
Local recurrence was the most common cause of death.
Lerch and co-workers [12] found no significant influence of
lymph node involvement on survival. In their group of 
500 patients, higher mortality of patients with lymph node
involvement was associated with high tumor stage (T4) and
presence of distant metastases (M1). They stated that lymph
node involvement may influence recurrence. Adjuvant exter-
nal beam radiotherapy was not used in their study.
Tubiana et al. [8] reported on 66 patients who received adju-
vant radiotherapy postoperatively for extensive regional
lymph node involvement, tumor invasion of the neighboring
muscles, or difficult surgical excision of recurrence after
previous operation. The relapse-free survival and the overall
survival rates for this group of patients given external beam
radiotherapy with or without 131I was lower than for the group
treated with surgery alone. However, external beam radio-
therapy was performed on patients with less favorable pro-
gnosis. When the high-risk cases were pooled with the patients
who had gross residual disease, the number of local recur-
rences was 14%, as compared to 21% out of 336 patients who
did not receive external beam radiotherapy (p < 0.05).
The importance of giving an adequate dose of external beam
radiotherapy was demonstrated by a lower infield recurrence
rate in patients who received doses greater than 50 Gy. These
results suggest that adequate external beam radiotherapy im-
proves local control in patients who are at risk of local relapse.
Benker and co-workers [13] from Essen/Germany reviewed
932 patients. 346 had undergone external beam radiotherapy
with a total dose from 40 to 70 Gy prior to 131I therapy. Survival
was not prolonged following postoperative external beam
radiotherapy. However, a subgroup analysis of patients older
than 40 years with tumors > 4 cm or with tumors with extra-
thyroidal extension, revealed a 10-year survival rate of 48% for
those treated without external beam radiotherapy as compared
to 58% for those who received external beam radiotherapy
(this difference was not statistically significant). More recently,
Farahati et al. [14], also from Essen, reported on an increased
freedom from locoregional and distant failure for patients over
the age of 40 with extrathyroidal extension and lymph node
involvement from papillary carcinoma who were treated with
adjuvant external radiation therapy. It is important to note,
that all patients had standard therapy of total thyroidectomy,
2 courses of 131I, and thyroid-stimulating hormone (TSH) sup-
pression. The only treatment variable was the use of adjuvant
external beam radiation therapy following the initial 131I therapy.
External beam radiation therapy was a predictive factor for
improvement in time locoregional recurrence (p = 0.004) and
locoregional and distant failure (p = 0.0003).
The participants of a German nuclear medicine meeting (1991,
in Heidelberg) [15] advocated adjuvant external radiotherapy
after surgery and ablative radioiodine therapy in patients suf-
fering from a well-differentiated thyroid carcinoma with extra-
thyroidal extension. Surgery is performed with the intention of
total thyroidectomy. Only in very few cases macroscopic re-
sidual tumor is present after surgery. In this case, if second
surgery is not possible, we would recommend to give 131I therapy
followed by external beam radiotherapy and to continue with
131I therapy.
Prognostic Factors
Tennvall and co-workers [16] investigated other significant
prognostic factors than those proposed by the EORTC Co-
operative Group. The EORTC Co-operative Group identified
prognostic significance for age, sex, cell type, clinical extent of
tumor, lymph node involvement, and presence of distant metas-
tases. Adamietz and co-workers [2] identified the same factors
during their rather long median follow-up of 11 years with
advanced age being the most important prognostic factor.
In the study of Leisner et al. [1], men died 1.5 times more
frequently than women. The 10-year survival rate was 90% in
patients below the age of 50 years in contrast to 60% in older
patients. Patients with papillary carcinoma showed a 10-year
survival rate of 78%, whereas 66% of all patients with follicular
carcinomas survived longer than 10 years.
Saur and co-workers [3] also revealed age, tumor invasion, and
distant metastases as being of significant prognostic value. No
correlation was demonstrated for sex and tumor histology. The
authors recommend external beam radiotherapy in cases of
incomplete tumor resection, in the presence of lymphangiosis
carcinomatosa, and in anaplastic transformation.
Comparison of existing studies is difficult because of the di-
verse treatment modalities, e.g. extent of surgery, 131I therapy,
irradiated volume, and applied doses. Further obstacles are
introduced over the years by changes of the staging system.
The only way to define the role of external beam radiotherapy
is to perform a prospective randomized trial of external beam
radiotherapy against no external beam radiotherapy in patients
considered to be at increased risk of relapse in the thyroid bed.
Such a randomized trial has been opened for patient recruit-
ment in December 1999 by the University of Münster/
Germany. Results may be available in approximately 10 years.
Conclusions
In management of differentiated thyroid cancer, surgery and
131I therapy are standard treatment. The use of adjuvant exter-
nal radiotherapy remains controversial. Most authors recom-
mend adjuvant external radiotherapy for extracapsular tumor
extension. For patients with lymph node involvement the deci-
sion should be made with respect to the prognostic factors on
an individual basis. In the case of incomplete surgical resection,
external beam radiotherapy should be applied if re-operation
is not possible.
In the thyroid bed doses of 60–66 Gy should be applied. The
cervical lymph nodes up to the hyoid bone, the supra- and
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infraclavicular lymph nodes and the nodes in the ventral and
upper mediastinum should receive doses of 50 Gy using single
doses of 1.8–2.0 Gy. The dose at the spinal cord should be lim-
ited to 40 Gy.
The potential benefit of external irradiation must be weighted
against possible acute side effects (e.g. dry desquamation and
rarely moist desquamation, mucositis, and weight loss) and late
effects (fibrosis and nerve palsy). The acute side effects are
reversible. Due to their self-limiting nature a high frequency of
dry desquamation and mucositis can be accepted. The late side
effects are usually irreversible and therefore mostly considered
as the dose-limiting end point.However,with the recommended
doses the incidence of severe late effects is very low.
Medullary Thyroid Cancer
External irradiation for medullary thyroid cancer is discussed
controversially in the literature. Prospective randomized trials
have not yet been performed due to the rarity of the disease.
All reported series are retrospective by nature. Recent data
indicate that external radiotherapy can be used for curative
treatment in patients with microscopic residual or gross disease
after surgery [17, 18]. Tubiana et al. [8] reported similar survival
rates for patients who received postoperative irradiation and
for those who received surgery alone. Since the tumor was
more limited in the patient group who received surgery alone,
complete surgical excision was easier to achieve and involve-
ment of the cervical lymph nodes was less frequent and less
extensive [19]. Jensen and colleagues [20] reported on 5287 cases
of thyroid cancer. 191 patients (4%) suffered from medullary
cancer. 70% of these patients were treated with surgery alone.
Surgery plus irradiation showed 100% survival at 5 years, com-
pared with 91% survival after surgery alone.
In patients with microscopic residual disease the recommended
dose is 60 Gy administered within 6–7 weeks. In cases with
remnant gross disease or surgically unmanageable tumors,
65–70 Gy is advocated, with a reduced volume after 50–60 Gy.
With bone metastases or inoperable mediastinal lymph node
metastases, external irradiation is the most effective therapy
and yields prolonged palliation in 75% of the patients.
Conclusion
External beam irradiation seems to be beneficial for patients
with surgically inaccessible disease, for patients with micro-
scopic residual or gross postoperative disease, for patients with
recurrent locoregional disease, and in cases of metastases
which are impossible to manage by surgery [21].
Anaplastic Thyroid Cancer
Levendag and co-workers [22] reported on 51 patients with
anaplastic thyroid carcinoma. 45% had some kind of surgery,
however, only 1 had radical surgery with microscopically free
margins. 75% of the 28 patients without distant metastases at
the beginning of radiotherapy treatment developed distant
metastases within 6 months. The overall survival was poor.
94% died within the first year. Patients who received doses of
less than 30 Gy had a median survival of only 0.6 months,
which might be caused by the aggressive nature of the disease.
In contrast, patients who received doses above 60 Gy had the
best prognosis with 20% 1-year survival and a median survival
of 5.3 months.The main cause of death was residual tumor and
local relapse. Complete response to radiotherapy at the end of
treatment seems to correlate with the best prognosis (8 months
median survival vs 1.6 months for none or incomplete respond-
ing tumors). Junor et al. [23] noted higher survival rates with
increased radiation dose as well.
Combined Therapeutic Modality
Kim and Leeper [24] reported on 19 patients with anaplastic
giant and spindle cell carcinoma of the thyroid.10 of them under-
went subtotal thyroidectomy and modified neck dissection,
9 received only biopsy of the tumor. None of the patients
showed any evidence of distant metastases at the time of
treatment. After diagnosis, all of them received a combined
therapeutic regimen consisting of administration of adriamycin
(10 mg/m2, or a maximum of 20 mg), once weekly before hyper-
fractionated radiotherapy (1.6 Gy twice a day, 3 days/week, total
dose 57.6 Gy in 40 days) was performed. Initial complete tumor
response rate was 84%. Local tumor control rate 2 years after
combined therapy was 68%. The median survival time was
1 year, which is still significantly higher compared to the 
5.3 months found by Levendag et al. [22] with high-dose irradia-
tion alone. However, most patients promptly developed distant
metastases and died from tumor-related causes. Other authors
found similar results with combined radiochemotherapy [25,26].
Conclusion
Patients treated with combined extensive surgery, irradiation
with total doses up to 60 Gy, and chemotherapy, appear to have
the best survival rates.
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